by the numbers

Annual report highlights Houston's big innovation wins across tech, life science, space, VC funding, and more

The Greater Houston Partnership's annual Houston Facts report recently released. Here's what to know across the city's five most innovative sectors. Photo via Getty Images

Houston, a city known for its energy legacy, is rapidly transforming into a diverse hub of innovation, life science, technology, and aerospace, according to the 2023 Houston Facts report, released by the Greater Houston Partnership.

Here are some highlights from the report.

​The thriving tech ecosystem

Chart via 2023 Houston Facts

With over 230,800 tech workers representing 6.9 percent of the workforce, Houston has firmly established itself as a digital tech talent hub, per the report, which adds that the city is home to a staggering 9,100 tech-related firms, including more than 1,000 venture-backed startups. These startups have secured $6.42 billion in venture capital funding over the past five years, with $1.95 billion in funding in 2022 alone, according to GHP analysis of Pitchbook data.

Houston's technology landscape witnessed significant growth in 2022, with the most heavily invested industries being Energy, Information Technology, and Business Products and Services. A study by Dice revealed that Houston led all cities in tech job posting growth in 2022, boasting a remarkable 45.6 percent year-over-year increase.

Among Houston's largest employers are tech giants such as Asurion, AWS, Dell, HighRadius, HP Enterprise, HP Inc., IBM, PROS, BMC Software, Siemens, Honeywell, Oracle, and Microsoft.

Health startups and biotech advancements

Houston's health tech and life science innovation sector will continue to grow with Helix Park. Courtesy of Elkus Manfredi Architects

Houston's life science and biotech sector is continuing to develop, the GHP finds, with a vast pool of medical professionals, including over 161,800 healthcare practitioners and technical workers, as well as 15,400 life science and biotech researchers.

In 2022, several health startups received significant venture capital funding, showcasing Houston's commitment to advancing medical technologies. The largest deals were from: NuProbe, RadioMedix, Medical Informatics, XCath, Stream Biomedical, Decisio, Adient Medical, Coya Therapeutics, Octagos Health, and Luna Genetics. Collectively, these startups raised over $220 million in funding to develop innovative solutions in diagnostics, monitoring, therapeutics, and more.

The Texas Medical Center Innovation Factory serves as the nucleus of Houston's life science startup activity. With the TMC's Helix Park continuing to rise as an expanded campus, even more activity is on its way to Houston.

Growing innovation infrastructure

Houston's innovation corridor continues to develop. Mapvia 2023 Houston Facts

When it comes to the development of Houston's innovation ecosystem, the report called out a few milestones the region reached in 2022. Here are some of those wins from last year.

  • The Houston area grew to include more than 80 SDOs, including incubators and accelerators, makerspaces, coworking spaces, nonprofits, and academic institutions. Per the report, there are at least 30 incubator and accelerator programs currently running in Houston — including MassChallenge, Ion Smart Cities Accelerator, Gener8tor, JLABS, Greentown Labs, TMC Innovation and more.
  • The Houston Innovation corridor, which consists of a a four-mile expanse across the city’s urban core and is anchored by Rice University's Ion, continues to take shape.
  • Both Rice University and University of Houston held onto the top spots on The Princeton Review's report on top entrepreneurship programs. And, the annual Rice Business Plan Competition remains the richest pitch competition in the country, according to the Princeton Review, doling out nearly $2.0 million in prizes.

Aerospace advancement

Axiom Space — as well as a few other Houston space tech companies — had some big wins in 2022. Photo courtesy of NASA

Anchored by NASA's Johnson Space Center and the Houston Spaceport, the city's aerospace industry continues to play a major role in the future of space exploration and commercialization.

The Orion, Gateway, and Human Landing System programs, which are part of NASA's Artemis missions, are headquartered at JSC.

Three Houston space tech companies made major moves recently, as Houston Facts calls out:

  • Axiom Space broke ground on the first phase of a 22-acre campus that will house astronaut training and develop Axiom Station, a commercial module that will attach to the ISS.
  • Intuitive Machines, which went public last year, started construction on a 12.5-acre campus. "Intuitive will build lunar landers, operate its mission control center, and make guidance, navigation, and make guidance, navigation, and control products at its site," per Houston Facts.
  • Collins Aerospace, which has a significant presence in Houston, began operations at their eight-acre campus where it will develop systems for NASA’s human spaceflight programs. The company is working with Axiom Space to create the next generation of NASA spacesuits via a NASA contract that is valued at up to $3.5 billion.

Tracking the energy transition

Chart via 2023 Houston Facts

The report highlights the fact that last year Houston's energy transition brought in $6.1 billion in financing from private market investments, which represents a 61.9 percent increase compared to 2021.

"Over the last five years, Houston has seen constant growth in annual energy transition investments, with a notable surge observed from 2020 onwards," reads the report.

Corporate and strategic merger and acquisition investments are what dominated the five deal types, according to the report, representing 68.8 percent of the total investment in 2022. Additionally, private equity accounted for 19.3 percent of all deals, with venture capital comprising 9.5 percent.

EnergyCapital, a sister site to InnovationMap, covered the complete section on the energy industry in the Houston Facts in an article. Read it here.

------

This article was generated in part by artificial intelligence.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted